[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption] WALTHAM, Mass.,?Aug. 12, 2019?/PRNewswire/ --?Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and?Canada) to evaluate the combination of Oncologie's investigational drug Bavituximab, an antibody that blocks the activity of phosphatidylserine (PS), and Merck's anti-PD-1 therapy, KEYTRUDA? (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer. Under the terms of the agreement, Oncologie will conduct a Phase 2 single arm open-label study to determine the efficacy and safety of Bavituximab in combination with KEYTRUDA in patients who have advanced gastric and gastroesophageal cancer, after they have failed at least one line of treatment.? The study is expected to enroll approximately 80 patients in the U.S.,?United Kingdom, Korea and?Taiwan. The study is anticipated to start enrollment in the second half of 2019. "Gastric cancer is an area of significant unmet medical need in many parts of the world and we are committed to understanding the clinical benefit of Bavituximab and KEYTRUDA in this difficult-to-treat cancer," said?Laura Benjamin, Ph.D., Founder and CEO of Oncologie. "This collaboration reflects a shared commitment to the goal of improving the lives of cancer patients in meaningful ways." Keytruda? is a registered trademark of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.,?Kenilworth, NJ, USA.? About Bavituximab Bavituximab is an investigational chimeric monoclonal antibody that targets the activity of phosphatidylserine (PS). Bavituximab is believed to reverse PS-mediated immunosuppression by blocking the engagement of PS with its receptors.? PS-targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor immune responses.? This mechanism may play an important role in allowing other cancer therapies to more effectively attack tumors by reversing the immunosuppression that limits the impact of those treatments. Importantly, Bavituximab has also demonstrated a manageable safety and tolerability profile in previous clinical trials conducted to date, which may allow it to be combined effectively with other agents. About Oncologie, Inc. Oncologie, Inc. is an innovative biopharmaceutical company committed to delivering better outcomes for cancer patients through improved approaches to patient selection and clinical trial design.? Our current pipeline includes clinical programs that improve treatment outcomes by modulating the tumor micro-environment and enhancing the immune response to targeting cancer cells.? From its headquarters in?Boston, Massachusetts?and?Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world. Contact:
Heather Savelle?or?Ryan Baker
Argot Partners
212.600.1902
oncologie@argotpartners.com SOURCE Oncologie, Inc.